James Stewart puts on his rollerblades to get ready to do the trail in Rabb Park on his day off. He continues to be able to ...

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that adult patients ...

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the ...

Padcev is approved for use in combination with the programmed death 1 inhibitor Keytruda (pembrolizumab) or Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant treatment and ...

Relmada Therapeutics Inc ($RLMD) announced an update on their ongoing clinical study. Relmada Therapeutics is preparing to launch a late-stage ...

LOS ANGELES — A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had ...

Imagine a targeted approach to bladder cancer that spares healthy cells while delivering chemotherapy directly to cancerous ones, offering hope for patients with advanced stages of the disease.

CBS News medical contributor Dr. Celine Gounder breaks down bladder cancer symptoms and treatment after Deion Sanders recently opened up about his personal cancer battle. Girl, 9, Receives Rare ...

A significant breakthrough in advanced bladder cancer treatment has been approved for use on the NHS, offering renewed hope to patients and potentially doubling survival times. The innovative ...

MORNING COMMUTE. STARTING AT 4:30 A.M. PRO FOOTBALL HALL OF FAMER AND CURRENT COLLEGE FOOTBALL COACH DEION SANDERS REVEALED HE WAS DIAGNOSED WITH AN AGGRESSIVE FORM OF BLADDER CANCER EARLIER THIS YEAR ...

A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously ...